title: Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature.
abstract: Posterior reversible leukoencephalopathy syndrome (PRES) is a syndrome characterized by headache, hypertension, confusion, visual disturbance, and seizures accompanied by subcortical vasogenic edema, predominantly involving the parietal and occipital lobes. The syndrome is usually described in malignant hypertension, eclampsia, renal failure, immunosuppressive, and cytotoxic chemotherapies. Bevacizumab, a monoclonal antibody that binds to the vascular endothelial growth factor (VEGF) has been linked to PRES. We carried out review of reports documenting the occurrence of PRES in patients receiving bevacizumab. This literature review was conducted by utilizing PubMed Database. If early diagnosed, PRES is reversible. We present a case of fatal PRES-associated coma induced by bevacizumab in metastatic colorectal cancer.
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey drangelkarakurt@hotmail.com.
authors.forename: Melek Karakurt
authors.initials: MK
authors.lastname: Eryılmaz
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Derya Kıvrak
authors.initials: DK
authors.lastname: Salim
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Fatma Yalçın
authors.initials: FY
authors.lastname: Musri
authors.affiliation: Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: Hasan Şenol
authors.initials: HŞ
authors.lastname: Coşkun
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy*; D003128:Coma / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; D000068258:Bevacizumab
keywords: Bevacizumab; metastatic colorectal cancer; posterior reversible leukoencephalopathy syndrome